Key result
Study evaluates vascular risk of CGRP mAbs and gepants in migraine without reporting results.
Why the study?
To characterize patient demographics and vascular risk in individuals with migraine prescribed calcitonin gene-related peptide inhibitors, including monoclonal antibodies and antagonists.
Does the choice between CGRP monoclonal antibodies and gepants affect the risk of vascular outcomes in individuals with migraine?
Does the choice between CGRP monoclonal antibodies and gepants affect the risk of vascular outcomes in individuals with migraine?
Answers are grounded in this paper and cite their sources.
Maps real-world CGRP inhibitor use and vascular risks in migraine; leaves open long-term safety questions for practice and trials.
To characterize patient demographics and vascular risk in individuals with migraine prescribed calcitonin gene-related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and antagonists (gepants).
No takes yet. Share an insight, caveat, or question.
Franco et al. (2026) studied this question. CGRP monoclonal antibodies and gepants were assessed for vascular risk in patients with migraine, though the provided abstract only outlines the study objective without reporting results.
Synapse has enriched 10 related papers. Consider them for comparative context: